COVID-19 News

NCI experts discuss impact of COVID-19 on clinical trials of cancer therapies

When the coronavirus pandemic reached the United States, thousands of people with cancer were participating in clinical trials, including many at St. Jude Children’s Research Hospital in Memphis, Tennessee.

At St. Jude, investigators took steps to reduce the risk that children participating in clinical trials, including studies testing new cancer drugs, would become infected with the virus that causes COVID-19.

Limiting patient visits to the hospital was one strategy for preventing infections. So, instead of having patients come to the hospital for routine assessments, nurses went to the patients, who were staying with their families in housing provided by St. Jude. Teams of nurses, carrying backpacks with medical supplies and personal protective equipment, met with the children and provided basic care, such as collecting blood samples. The nurses essentially brought the clinical trials to the patients, an idea that has attracted new interest among researchers during the pandemic.

Another change made by St. Jude was to begin virtual research visits between health care providers and patients. Some of the nurses who visited patients staying at St. Jude had been trained to help with telehealth visits.

A greater use of telemedicine has emerged as one of the positive changes to cancer clinical trials that could be continued after the pandemic has passed, according to the results of two surveys of clinical trial investigators and a series of recent commentaries by leaders of clinical trials.

Other changes to trials during the pandemic that could be incorporated into future studies include the use of electronic signatures for patient consent forms, remote monitoring of clinical trial results, and shipping oral medications directly to patients participating in clinical trials.

“We’ve learned some lessons,” said William Dahut, MD, scientific director for clinical research at NCI’s Center for Cancer Research, who conducts clinical trials. “My hope is that we emerge from this period with improvements in the way we conduct cancer clinical trials.”

In the past, such changes might have been viewed as violations of study protocols. But, in March, NCI provided guidance for clinical trial activities affected by the coronavirus. The Food and Drug Administration also issued a guidance on clinical trials of medical products during the pandemic.

“We have been closely monitoring NCI-sponsored clinical trials to understand how we can make accommodations so that patients can receive care while the clinical trial investigators can, as much as possible, continue the studies,” said Meg Mooney, MD, of NCI’s Cancer Therapy Evaluation Program.

NCI has given trial sites flexibility in the operations of trials, including in the timing of when patient tests and assessments must be done.

“Investigators leading clinical trials can work with the Institutional Review Board that oversees each study protocol to make necessary adjustments,” Mooney explained. “These modifications will provide flexibility without compromising patient safety or the validity of the data being collected by the trial.”

A Sense of the Unknown

Clinical trials are critical for progress against cancer. And trials that evaluate new therapies are often the best, or the only, treatment option for some patients. During the pandemic, NCI continued to enroll clinical trial participants for whom the NIH Clinical Center, located in Bethesda, MD, had the most appropriate treatments.

The biggest challenge in the first weeks of the pandemic “was a sense of the unknown,” Dahut said.

Travel restrictions and other measures put in place to reduce the spread of the novel coronavirus raised questions about how to care for patients who travel long distances to come to their appointments. Should these patients even make the trip to Bethesda? Should their treatments be given on a different schedule, such as every 6 weeks rather than every 4 weeks?

“We were trying to find the balance between treating patients for their cancers and ensuring that the patients were safe while traveling,” he said. But the researchers had limited information to guide their decisions, he added.

Patients who are taking a new drug should be seen once a week, Dahut noted, but this can often be done virtually.

“Most experienced investigators can get a pretty good sense of how someone’s doing by looking at the person during a virtual visit,” he said, adding that patients who are seen virtually need to be in contact with local physicians who can provide immediate medical attention if necessary.

Another attractive feature of telehealth is the ability for family members who live far from a patient to participate in a conversation with doctors, Dahut said.

“Through telehealth technologies, a physician could invite a son or daughter immediately into the conversation, allowing the child to hear the discussion and see the body language of the parent,” he said.

At the same time, Dahut and his colleagues have been trying to reduce the number of required tests and patient visits to the Clinical Center without compromising patient safety and the scientific integrity of the clinical trials. To do this, the researchers carefully evaluate each patient and consult with the Institutional Review Board and sponsor of the trial, according to a commentary cowritten by Dahut on what clinical trials might look like after COVID-19.

Surveys Provide a Snapshot of Changes in Clinical Trials

Early in the pandemic, leaders at the American Society of Clinical Oncology realized that clinical trials would be affected, so they developed a survey to capture some of these changes. Conducted in late March, the survey elicited responses from 32 investigators, including 14 who represented academic programs and 18 who represented community-based programs.

“The survey was a snapshot of what people were seeing and feeling at that time, and I think it serves as a motivator to make the necessary changes to improve the clinical research system,” said David Waterhouse, MD, of Oncology Hematology Care in Cincinnati, who co-led the survey. “Telemedicine was probably the most widely adopted solution to the challenge of getting patients seen and making sure they were taken care of during the pandemic.”

Waterhouse noted that not every patient can travel to cancer centers for treatment and that this can lead to disparities in care.

“A goal for the future is to bring clinical trials to the patient rather than making the patient come to the trial,” he said, adding that telemedicine would likely play an important role.

A majority of investigators who responded said their institutions had developed formal policies related to the COVID-19 pandemic. In three-quarters of the respondents’ programs, research staff were mandated to work remotely.

Delays in clinical research activities were common, the survey found. A majority of respondents’ programs stopped cancer screening and/or enrollment for certain clinical trials, including those that were conducted for research purposes only.

“Many cancer centers began to prioritize which trials could continue to enroll patients based on the severity of the disease and the treatment options available to a patient, and also on the center’s own staffing,” Waterhouse said.

These findings were consistent with the results of a second survey involving 36 investigators that was conducted between March 23 and April 3. The enrollment of patients in active cancer clinical trials decreased during the survey period. In the United States and Europe, only 20% and 14%, respectively, of the institutions continued to enroll patients at the usual rate.

Clinical Trials in the Community

In the United States, the impact of the pandemic on cancer clinical trials has varied depending on the extent of COVID-19 in the areas where the studies have been conducted. This has been seen across NCI’s Community Oncology Research Program (NCORP), which conducts clinical trials at more than 1,000 sites in 43 states plus the District of Columbia, Puerto Rico, and Guam. Some are in rural areas and others are in urban centers. NCORP includes 14 sites that are designated as Minority/Underserved Community Sites.

In addition to participating in cancer treatment trials, NCORP also conducts trials in cancer prevention, screening, symptom management, and the delivery of cancer care.

At the start of the pandemic, NCORP determined that providing care for those patients who are undergoing treatment for cancer was the priority, according to Worta McCaskill-Stevens, MD, chief of NCI’s Community Oncology and Prevention Trials Research Group, which includes NCORP.

NCORP provided sites with guidance on how to modify trials during the pandemic, allowing the remote signing of consent forms and virtual follow-up meetings with doctors. Patients who could not travel to their primary clinical trial sites were allowed to go to another site or to a local health care provider.

“From NCORP’s diverse oncology practices, including cities and rural areas, NCI is capturing valuable information about the resiliency of community investigators during crises and about their commitment to cancer care and research,” McCaskill-Stevens said.

Some rural oncology practices that were already using telemedicine relied on this mechanism during the pandemic to maintain as much of their clinical practices as possible, she noted. Some of the Minority/Underserved Community Sites in cities were more challenged by the pandemic.

“Two NCORP hospitals in New York City, Columbia and Montefiore, focused their resources on caring for people with COVID-19,” McCaskill-Stevens said. “The heroic efforts of health care providers and staffs at these hospitals were widely covered by the news media.”

In Chicago, she noted, the Cook County NCORP was forced to temporarily close its chemotherapy unit after members of the cancer treatment team were possibly exposed to the coronavirus.

“The pandemic has challenged the practice of oncology as we know it,” McCaskill-Stevens said.

Expanding the Reach of Clinical Trials

Travel to clinical trial sites has been a longstanding burden for some patients participating in clinical trials and may contribute to disparities in who is served by these studies, noted Eric J. Small, MD, who studies and treats patients with prostate cancer at the University of California, San Francisco.

But the pandemic has created an opportunity to review current practices in cancer clinical trials, including how frequently patients in certain trials need to be seen for in-person assessments, Small wrote in a commentary on the urgent need for transformation in cancer clinical trials.

“We’re learning that we can do a lot more remotely than we might have thought,” Small said. “Obviously, there are some situations where we have to see the patient, but I think we have learned that having the flexibility of being able to use telemedicine is important. We’ve also learned that assessing the patient’s response to treatments every six weeks might be a little too often and that nothing is lost by doing it every three months.”

He is optimistic that, in the coming months and years, the lessons learned during the pandemic will lead to changes, such as the expanded use of telemedicine, that make trials more accessible.”

“My hope is that we can be more broadly inclusive to serve underserved populations," Small said, "particularly people in rural areas.”

Read more: